Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicentre Study to Evaluate Pharmacokinetics, Safety and Efficacy of Zamicastat as Adjunctive Therapy in Pulmonary Arterial Hypertension (PAH)

NCT04316143 is registered in ClinicalTrials.gov with Bial - Portela C S.A. as lead sponsor.

NCT NCT04316143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04316143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicentre Study to Evaluate Pharmacokinetics, Safety and Efficacy of Zamicastat as Adjunctive Therapy in Pulmonary Arterial Hypertension (PAH)
Lead sponsor
Bial - Portela C S.A.
Phase
Phase 2
Overall status
Completed
Start date
June 3, 2019
Completion date
October 20, 2021
Enrollment
33 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension